Menu Search
Equities

BioInvent International AB

BOVNF:PKL

BioInvent International AB

Actions
  • Price (USD)4.70
  • Today's Change0.00 / 0.00%
  • Shares traded3.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 22 2024 15:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

  • Revenue in SEK (TTM)38.64m
  • Net income in SEK-409.65m
  • Incorporated1997
  • Employees115.00
  • Location
    BioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
  • Phone+46 462868550
  • Fax+46 462110806
  • Websitehttps://www.bioinvent.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.